Coexistence of Type-1 Diabetes Mellitus and Papillary Thyroid Carcinoma

Author(s): Murat Calapkulu*, Muhammed Erkam Sencar, Hakan Duger, Seyit Murat Bayram, Ilknur Ozturk Unsal, Erman Cakal, Mustafa Ozbek

Journal Name: Current Diabetes Reviews

Volume 16 , Issue 7 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

İntroduction: Type 1 diabetes mellitus (DM) is characterized by selective autoimmune destruction of pancreatic b-cells, resulting in insulin deficiency and associated autoimmune disorders, such as celiac disease, autoimmune thyroiditis, and gastritis, which can coexist in patients with type 1 DM. These disorders are characterized by the presence of antibodies against tissue transglutaminase, thyroglobulin, and thyroid peroxidase (TPO), as well as against gastric parietal cells. Cross-sectional studies have reported that the risk of autoimmune thyroid diseases in patients with type-1 DM is two- to threefold higher than in the general population. However, there are a few studies in the literature that investigated the relationship between malignancy and type-1 DM, and it has been shown that type-1 DM does not increase thyroid cancer. Furthermore, there is a lot of controversy regarding the role of thyroid autoimmunity in the pathogenesis of thyroid cancer. Here, a type-1 DM patient diagnosed with papillary thyroid cancer is presented.

Case Report: Herein, it was aimed to present a 20-year-old female patient diagnosed with type-1 DM and subsequently with papillary thyroid carcinoma (PTC). Thyroid ultrasound revealed a 10×12×18 mm hypoechoic irregular edges nodule with macrocalcification and microcalcification foci in the left lobe and pathological lymph nodes without echogenic hilus were detected at the fourth level of the left cervical chain. Fine needle aspiration biopsy of the nodule was consistent with papillary thyroid carcinoma. Total thyroidectomy, bilateral central lymph node dissection, and left neck dissection (level II to IV) were performed. Pathological examination revealed a 1.4× 0.9 cm diameter papillary carcinoma located in the left lobe of the thyroid gland with 13 lymph node metastases.

Conclusion: Patients with type 1 DM should be examined for thyroid diseases, and patients with suspected thyroid disease should be evaluated with a thyroid ultrasound. Type 1 DM and PTC can coexist, albeit very rare. It should be known that type 1 diabetes can be observed together with thyroid cancer.

Keywords: Type-1 diabetes, thyroid cancer, papillary thyroid cancer, anti-thyroid peroxidase, carcinoma, thyroid gland.

[1]
Umpierrez GE, Latif KA, Murphy MB, et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care 2003; 26(4): 1181-5.
[http://dx.doi.org/10.2337/diacare.26.4.1181] [PMID: 12663594]
[2]
Aschebrook-Kilfoy B, Sabra MM, Brenner A, et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid 2011; 21(9): 957-63.
[http://dx.doi.org/10.1089/thy.2010.0396] [PMID: 21767143]
[3]
Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89(18): 1360-5.
[http://dx.doi.org/10.1093/jnci/89.18.1360] [PMID: 9308706]
[4]
Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 1997; 6(11): 863-73.
[PMID: 9367058]
[5]
Yeo Y, Ma S-H, Hwang Y, et al. Diabetes mellitus and risk of thyroid cancer: a meta-analysis. PLoS One 2014; 9(6)e98135
[http://dx.doi.org/10.1371/journal.pone.0098135] [PMID: 24927125]
[6]
Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care 2015; 38(2): 264-70.
[http://dx.doi.org/10.2337/dc14-1996] [PMID: 25488912]
[7]
Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 2010; 27(7): 791-7.
[http://dx.doi.org/10.1111/j.1464-5491.2010.03011.x] [PMID: 20636960]
[8]
Carstensen B, Read SH, Friis S, et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia 2016; 59(5): 980-8.
[http://dx.doi.org/10.1007/s00125-016-3884-9] [PMID: 26924393]
[9]
Karavanaki K, Karayianni C, Vassiliou I, et al. Multiple autoimmunity, type 1 diabetes (T1DM), autoimmune thyroiditis and thyroid cancer: is there an association? A case report and literature review. J Pediatr Endocrinol Metab 2014; 27(9-10): 1011-6.
[http://dx.doi.org/10.1515/jpem-2013-0370] [PMID: 24854531]
[10]
Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care 2015;38:264-270. Diabetes Care 2015; 38(4): 734-5.
[PMID: 25805866]
[11]
Völzke H, Krohn U, Wallaschofski H, Lüdemann J, John U, Kerner W. The spectrum of thyroid disorders in adult type 1 diabetes mellitus. Diabetes Metab Res Rev 2007; 23(3): 227-33.
[http://dx.doi.org/10.1002/dmrr.676] [PMID: 16906626]
[12]
Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2009; 32(Suppl. 1): S62-7.
[http://dx.doi.org/10.2337/dc09-S062] [PMID: 19118289]
[13]
Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18(3): 784-91.
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0960] [PMID: 19240234]
[14]
Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011; 128(3): 635-43.
[http://dx.doi.org/10.1002/ijc.25362] [PMID: 20473855]
[15]
Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol 2006; 169(5): 1505-22.
[http://dx.doi.org/10.2353/ajpath.2006.051090] [PMID: 17071576]
[16]
Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24(2): 68-72.
[http://dx.doi.org/10.1016/S0968-0004(98)01344-9] [PMID: 10098401]
[17]
Köhrle J. Local activation and inactivation of thyroid hormones: the deiodinase family. Mol Cell Endocrinol 1999; 151(1-2): 103-19.
[http://dx.doi.org/10.1016/S0303-7207(99)00040-4] [PMID: 10411325]
[18]
Krátký J, Ježková J, Kosák M, et al. Positive Antithyroid Antibodies and Nonsuppressed TSH Are Associated with Thyroid Cancer: A Retrospective Cross-Sectional Study. Int J Endocrinol 2018; 20189793850
[http://dx.doi.org/10.1155/2018/9793850] [PMID: 30258461]
[19]
Graceffa G, Patrone R, Vieni S, et al. Association between Hashimoto’s thyroiditis and papillary thyroid carcinoma: a retrospective analysis of 305 patients. BMC Endocr Disord 2019; 19(Suppl. 1): 26.
[http://dx.doi.org/10.1186/s12902-019-0351-x] [PMID: 31142293]
[20]
Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer 2009; 16(4): 1065-72.
[http://dx.doi.org/10.1677/ERC-09-0150] [PMID: 19620248]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 7
Year: 2020
Published on: 23 July, 2020
Page: [787 - 789]
Pages: 3
DOI: 10.2174/1573399815666191104114551
Price: $65

Article Metrics

PDF: 11
HTML: 2